Skip to: Content
Skip to: Site Navigation
Skip to: Search

December 2, 2008 5:15:09 AM CST



Dutch Pharma Firm Preps Pot Pill

Posted Jan 27, 08 1:31 PM CST in Business Science & Health 

(Newser) – Why smoke pot when you can pop a pill? Echo Pharmaceuticals is jumping into Phase II trials for a new cannabis pill that could snag 20%-30% of the booming medical marijuana market, Reuters reports. The Dutch firm plans to sell the pill within 5 years, giving medical marijuana users a healthier way to take the drug.

Echo may even beat its usual 5-year track to tackle a $5.85 billion worldwide market, where a Canadian company is the only competition. “We have an easy case, as the effects of the drug have been known for thousands of years,” said Echo’s CEO. Echo plans to start clinical trials this year and market the drug as Namisol, targeted to victims of migraines, MS, Parkinson's, and even Alzheimer's.

Source Reuters

0 comments | Print E-mail | Digg Seed this on Newsvine Add this link to Del.icio.us StumbleUpon
A marijuana plant is seen in this undated file photo.   (Shutterstock)
When cannabis is ingested in pill form, it is safer to ingest, experts say.   (Shutterstock)
« Prev« Prev | Next »Next » Slideshow
Our editors also recommend:

Threads (
1
 of 3)



Loading...

Premium Articles from HighBeam

Find more articles like this

Today's Most Popular

Loading...

Other Science & Health Stories


What is Newser?

2008 Codie Finalist

Face it: there's too much news. At Newser a team of editors and writers culls the most important stories from hundreds of U.S. and international sources and reduces them to a headline, picture, and two paragraphs. It's the Newser guarantee: we can take any report or column or video and pack what you need to know into 120 words or less. Newser's short-form aggregation, visual format, and unique information tools help you get more of the kind of news you want, in a quicker and more entertaining way. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »